(R)-(-)-2-甲基哌啶 | 1722-95-8

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: (R)-(-)-2-甲基哌啶
• 中文别名: (R)-2-甲基哌啶
• 英文名称: (2R)-methylpiperidine
• 英文别名: (R)-2-methylpiperidine；(2R)-2-methylpiperidine；2-methylpiperidine
• CAS: 1722-95-8
• 化学式: C₆H₁₃N
• 分子量: 99.1759
• InChiKey: NNWUEBIEOFQMSS-ZCFIWIBFSA-N

物化性质

• 熔点：
  118-121℃
• 沸点：
  118.8±0.0 °C(Predicted)
• 密度：
  0.809±0.06 g/cm3(Predicted)
• 蒸汽压力：
  19.31 mmHg

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933399090
• WGK Germany：
  3
• 包装等级：
  II
• 危险类别：
  3,8
• 危险性防范说明：
  P210,P261,P280,P305+P351+P338
• 危险品运输编号：
  2733
• 危险性描述：
  H225,H302,H315,H317,H318,H335
• 储存条件：
  存储条件：2-8°C，避光，使用惰性气体保护，并保持干燥。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (R)-2-Methylpiperidine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: (R)-2-Methylpiperidine
CAS number: 1722-95-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H13N
Molecular weight: 99.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (R)-(-)-2-甲基哌啶 在 potassium carbonate 、 一水合肼 、 sodium sulfate 作用下， 以 甲醇 、 乙醇 、 乙腈 为溶剂， 反应 33.0h， 生成 (R)-N,N'-(1,4-phenylenebis(methylene))bis(3-((R)-2-methylpiperidin-1-yl)propan-1-amine)
  参考文献：
  名称：

  Noncyclam Tetraamines抑制CXC趋化因子受体4型和靶向胶质瘤启动细胞。

  摘要：

  由（S）-和（R）制备非环酰胺化合物1（1（R，R），1（S，S）和内消旋体1（S，R））的三种立体异构体及其相应的四盐酸盐11。 -2-甲基哌啶。与原型化合物AMD3100相比，我们评估了它们对4型CXC趋化因子受体（CXCR4）的抑制活性，毒性性质以及对神经胶质瘤起始细胞（GIC）的影响。IC 50在人重组（CHO）细胞上测得的Rb值显示出非常相似的抑制活性，尽管AMD3100的K B较低，其中1（R，R）异构体的效力第二。所有化合物均显示出较低的心脏毒性，但与AMD3100相反，其最大非致死剂量约为2.0 mg / kg。CXCR4抑制剂对GIC的分化状态有影响，从而降低了成胶质细胞瘤多种形式的神经球中CD44 +细胞的百分比。此外，这些CXCR4抑制剂在免疫功能低下的小鼠中阻断了细胞引发原位肿瘤的能力。

  DOI：

  10.1021/jm300862u
• 作为产物：
  描述：

  2-甲基哌啶 在 葡萄糖 、 Streptomyces sp. GF₃₅₈₇ imine reductase 、 nicotinamide adenine dinucleotide phosphate 作用下， 以 aq. phosphate buffer 、 二甲基亚砜 为溶剂， 生成 (R)-(-)-2-甲基哌啶
  参考文献：
  名称：

  具有亚胺还原酶活性的三种新型酶的表征

  摘要：

  亚胺还原酶（IRED）是用于合成光学纯仲环胺的有前途的催化剂。通过氨基酸或结构相似性鉴定，鉴定了三种来自埃希氏Paenibacillus elgii B69，链霉菌91-03和恶臭假单胞菌KT2440的新型IRED，在大肠杆菌中克隆和重组表达，并研究了其底物范围。除了可以接受环胺外，无环胺还可以被确定为所有IRED的底物。对于恶臭假单胞菌的IRED，数据库中提供了晶体结构（PDB代码3L6D），但迄今为止尚未研究蛋白质的功能。该酶表现出最高的表观E这项研究中所研究的IRED的 （R）-甲基吡咯烷的大约E app = 52的值。因此，在24小时后使用静息细胞进行的生物催化反应中，对映体的纯度> 99％，转化率达到97％。有趣的是，可以通过诱变将组氨酸残基确认为催化残基，但是与卡那链霉菌IRED的催化Asp187的形式上已知的位置相比，该残基被放置了一圈。

  DOI：

  10.1016/j.molcatb.2014.09.017
• 作为试剂：
  描述：

  m-acetoxyphenylpropanoyl chloride 、 (E)-N-{2-[(S)-1-(tert-Butyl-dimethyl-silanyloxy)-2-methyl-propyl]-4-oxo-4H-quinazolin-3-yl}-3-phenyl-acrylamide 在 吡啶 、 (R)-(-)-2-甲基哌啶 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 Acetic acid 3-(3-{{2-[(S)-1-(tert-butyl-dimethyl-silanyloxy)-2-methyl-propyl]-4-oxo-4H-quinazolin-3-yl}-[(E)-(3-phenyl-acryloyl)]-amino}-3-oxo-propyl)-phenyl ester
  参考文献：
  名称：

  Parallel kinetic resolution of racemic amines using 3-N,N-diacylaminoquinazolin-4(3H)-ones

  摘要：

  对映体纯 3-[N-(3-m-乙酰氧基苯基丙酰基)-N-(3-苯基丙酰基)胺]-2-异丙基喹唑啉-4(3H)-酮 7 的两个假对映体 N-酰基分别与 2-甲基哌啶的不同对映体发生反应，从而产生高效的平行动力学解析（ee > 95%）。

  DOI：

  10.1039/b109297a

文献信息

• Preparation andIn Vitro Pharmacology of 5-HT4 Receptor Ligands. Partial Agonism and Antagonism of Metoclopramide Analogous Benzoic Esters
  作者：Sigurd Elz、Andreas Keller

  DOI：10.1002/ardp.19953280705

  日期：——

  functional in vitro assays with regard to affinity for serotoninergic 5‐HT4, 5‐HT3 and muscarinic M3 receptors. The affinities for 5‐HT4 and M3 receptors were below 6.0 (pKB or pA2). On 5‐HT4 receptors in guinea‐pig ileal longitudinal muscle and rat oesophagus, the majority of compounds revealed partial 5‐HT4 receptor agonism susceptible to blockade by SDZ 205557, a reference 5‐HT4 receptor antagonist

  胃促动力苯甲酰胺甲氧氯普胺 (1) 的脂环酯类似物及其酯同源物 SDZ 205557 (2)，一种 5-HT4 受体拮抗剂，通过 4-氨基-5-氯-2-甲氧基苯甲酸酯与 N-( 2-氯乙基）取代的脂环胺。化合物13b的溴和碘类似物（2-（1-哌啶基）乙基4-氨基-5-氯-2-甲氧基苯甲酸酯）通过脱氯-13b与N-卤代琥珀酰亚胺的卤化得到。在功能性体外试验中评估了该系列对 5-羟色胺能 5-HT4、5-HT3 和毒蕈碱 M3 受体的亲和力。5-HT4 和 M3 受体的亲和力低于 6.0（pKB 或 pA2）。在豚鼠回肠纵肌和大鼠食管中的 5-HT4 受体上，大多数化合物显示出部分 5-HT4 受体激动作用，容易被 SDZ 205557 阻断，参考 5-HT4 受体拮抗剂（pKb = 7.25 - 7.73（豚鼠回肠）和 7.09 - 7.43（大鼠食道））。相对激动剂效力在 5-303% (5-HT:
• BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND
  申请人：MITSUBISHI TANABE PHARMA CORPORATION

  公开号：US20190185479A1

  公开（公告）日：2019-06-20

  The present invention provides: a novel use of a specific bicyclic nitrogen-containing heterocyclic compound as a PDE7 inhibitor; a novel bicyclic nitrogen-containing heterocyclic compound having a PDE7 inhibitory effect, a method for producing the compound, a use of the compound, and a pharmaceutical composition containing the PDE7 inhibitor or the compound; and others. More specifically, the present invention provides a PDE7 inhibitor containing the compound represented by the formula (I): [wherein the symbols have the same meanings as those described in the description] or a pharmaceutically acceptable salt thereof as an active ingredient.

  本发明提供了：一种将特定的双环氮杂环化合物用作PDE7抑制剂的新用途；具有PDE7抑制作用的新型双环氮杂环化合物，一种制备该化合物的方法，该化合物的用途，以及含有PDE7抑制剂或该化合物的药物组合物；等等。更具体地，本发明提供了一种包含由下式（I）表示的化合物的PDE7抑制剂： [其中符号的含义与描述中所述的相同]或其药学上可接受的盐作为活性成分。
• Kinetic resolution of amines with enantiopure 3-N,N-diacylaminoquinazolin-4(3H)-ones
  作者：Al-Sehemi, Abdullah G.、Atkinson, Robert S.、Fawcett, John

  DOI：10.1039/b105917n

  日期：2002.1.7

  The title compounds (DAQs) are chiral when the two N-acyl groups are different because of the absence of rotation around the N–N bond (a chiral axis). Enantiopure DAQs have been obtained by incorporation of a chiral centre in enantiopure form either into the substituent at the Q2-position or into one of the N-acyl groups, or into both, followed by separation of diastereoisomers. This separation is unnecessary in one case because conversion of the N-monoacylaminoquinazolinone (MAQ) into the DAQ is completely diastereoselective. Neither is separation of diastereoisomers necessary with 3-[N,N-di-(S)-2-acetoxypropanoylamino]-2-diphenylmethylquinazolin-4(3H)-one 37a: this DAQ 37a has its N–N bond rendered a chiral axis by the bias in its imide moiety wholly in favour of one exo/endo conformation.The high chemoselectivity exhibited by N,N-diacetyl- or N,N-dibenzoylaminoquinazolinones in reaction with the less hindered of two secondary amines (pyrrolidine in the presence of 1 eq. of piperidine) has a stereoselective counterpart: reaction of the above enantiopure DAQs enantioselectively with racemic amines leading to kinetic resolution. Using 1 eq. of DAQ and 2 eq. of amine, both the derivatised and unreacted amine enantiomers are recovered with high enantiomeric excess (ee) (better than 90% ee in some cases). Some of the higher ees are found in the recovered amides where non-chemoselective attack on both N-acyl groups of the DAQ has occurred: from the opposite configurations of the amine component in the two amides and from the low enantiopurity of the recovered unreacted amine, reaction of each of the N-acyl groups with complementary enantiomers of the amine is occurring (parallel kinetic resolution).Although higher ees are, in general, obtained using secondary amines, high ees are obtained in some cases using 1-phenylethylamine and, in particular, amino acid esters (valine and alanine).The sense of enantioselectivity in the reactions of these DAQs with amines is controlled by the configuration of the N–N axis: replacing the Q group in an N-(S)-2-acetoxypropanoyl-N-acetyl-bearing DAQ by phthalimide, thus eliminating the N–N chiral axis, drastically reduces the level of kinetic resolution.

  标题化合物(DAQs)在两个N-酰基团不同时是手性的，因为N-N键（一个手性轴）缺乏旋转。通过将手性中心以手性形式引入Q2-位点的取代基或其中一个N-酰基团，或两者中，随后分离diastereoisomers，得到了纯对映体的DAQs。在一个情况下，这种分离是不必要的，因为将N-单酰胺基喹唑啉酮(MAQ)转化为DAQ是完全立体选择性的。对于3-[N,N-di-(S)-2-乙酰氧基丙酰胺基]-2-二苯甲基喹唑啉-4(3H)-酮37a，也不需要分离diastereoisomers：这个DAQ 37a通过其亚胺部分的偏向完全倾向于一个exo/endo构象，使其N-N键成为一个手性轴。N,N-二乙酰基或N,N-二苯甲酰氨基喹唑啉酮在与两个次级胺中较少受到阻碍的胺（在存在1 eq.的哌啶的情况下使用吡咯烷）反应时表现出高度的化学选择性，这在立体选择性上有对应：上述纯对映体的DAQs与外消旋胺反应，导致动力学拆分。使用1 eq.的DAQ和2 eq.的胺，衍生化的和未反应的胺对映体都以高对映体过量（ee）回收（在一些情况下优于90% ee）。在一些回收的酰胺中发现较高的ee，其中非化学选择性地攻击DAQ的两个N-酰基团：从两个酰胺中胺组分的相反构型和回收的未反应胺的低对映纯度，每个N-酰基团与胺的互补对映体反应（并行动态拆分）。尽管通常使用次级胺得到较高的ee，但在某些情况下使用1-苯乙胺，特别是氨基酸酯（缬氨酸和丙氨酸）得到高ee。这些DAQs与胺反应的对映选择性的方向受N-N轴配置的控制：在带有N-(S)-2-乙酰氧基丙酰基-N-乙酰基的DAQ中，通过用邻苯二甲酰亚胺替换Q组，从而消除N-N手性轴，显著降低了动力学拆分的水平。
• [EN] NOVEL HEPATITIS C VIRUS INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：MEDIVIR AB

  公开号：WO2013095275A1

  公开（公告）日：2013-06-27

  The invention provides compounds of formula (I): wherein Rings A and A' are independently 5-membered optionally substituted aromatic heterocycles; Q is C(=O)NR1R1' or formula U is C(R4)2, O, S, S(=O)2, C(R4)2C(R4)2, CH2O, OCH2, CH2S, SCH2, CH2S(=O)2, S(=O)CH2 or C=C(Ru )2; X is CH2, CHR12, CR12R12, O, S, S(=O)2 or NRx; m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.

  本发明提供了式(I)的化合物：其中环A和A'独立地是5个成员的可选取代的芳香杂环；Q是C(=O)NR1R1'或式U是C(R4)2，O，S，S(=O)2，C(R4)2C(R4)2，CH2O，OCH2，CH2S，SCH2，CH2S(=O)2，S(=O)CH2或C=C(Ru)2；X是CH2，CHR12，CR12R12，O，S，S(=O)2或NRx；m是0，1，2或3；n是0，1，2或3；其他变量如权利要求中所定义，用于治疗或预防丙型肝炎病毒感染，以及相关方面。
• Chelate-Controlled Asymmetric Synthesis of 2-Substituted 2,3-Dihydropyridin-4(1H)-ones: Synthesis ofD- andL-aminodeoxyaltrose derivatives
  作者：Jacques Streith、Arnaud Boiron、Jean-Louis Paillaud、Elsa-Maria Rodriguez-Perez、Christiane Strehler、Th�ophile Tschamber、Margareta Zehnder

  DOI：10.1002/hlca.19950780106

  日期：1995.2.8

  Asymmetric methylation and phenylation of the chiral pyridinium salt 7, as well as methylation of chiral pyridinium salt 18, with Grignard reagents occurred in good yield and with good-to-excellent diastereoselectivities (Schemes 2 and 3, resp.). These results are best explained by assuming chelate control to govern the asymmetric alkylation/arylation process. The minimum-energy conformations of the

  不对称甲基化和手性的吡啶鎓盐的苯基化7，以及手性的吡啶鎓盐的甲基化18，与格氏试剂发生在良好的产率和具有良好至优秀非对映选择性（方案2和3，RESP）。通过假定螯合剂控制非对称烷基化/芳基化过程，可以最好地解释这些结果。由“分子模拟Cerius-Dreiding II”程序确定的面外扭曲吡啶鎓盐7和18的最小能量构象与假定的不对称螯合物控制机制高度吻合。